Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003

Cosset, Jean‐Marc; Flam, T.; Belin, Lisa; Thiounn, Nicolas; Pierrat, N.; Pontvert, D.; Wakil, G.; Savignoni, Alexia; Chauveinc, L.

doi:10.1016/j.canrad.2016.02.009

Cited by 28 publications

(15 citation statements)

References 40 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our present findings are consistent with the results from other large series on LDR‐BT . For example, Sylvester et al examined a cohort of 215 patients with stage T1a–T3 prostate cancer treated with 125 I‐BT monotherapy and reported a 15‐year BFFS rate of 80.4% at a median follow‐up of 11.7 years.…”

Section: Discussionsupporting

confidence: 92%

“…The present study shows that 18% of patients with biochemical relapse and 35% with distant recurrence fail at >10 years after treatment. These data parallel findings of another large retrospective analysis of 675 patients treated with LDR‐BT, with or without ADT, which documented a total of 26% of all relapses in the second decade after implantation . Therefore, it is essential that physicians treating these patients counsel them on the possibility of late disease recurrence at >10 years after treatment and discuss the importance of continued follow‐up.…”

Section: Discussionsupporting

confidence: 70%

“…Few groups analysing the effectiveness of definitive LDR‐BT followed their patients for a median of ≥10 years . As the choice of definitive therapy in the context of prostate cancer is often driven by patient's knowledge of long‐term toxicity profile of a recommended treatment, data on late sequelae of LDR‐BT beyond the first decade of follow‐up become essential.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Low‐dose‐rate brachytherapy for prostate cancer: outcomes at >10 years of follow‐up

et al. 2018

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionsupporting

confidence: 70%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Low‐dose‐rate brachytherapy for prostate cancer: outcomes at >10 years of follow‐up

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The implantation took place using a peripheral loading technique and involved iodine-125 sources, an MR– compatible perineal template and catheters, and an intraoperative 0.5-Tesla MRI scanner. Long-term biochemical control results were disappointing for patients with favorable intermediate disease (36, 37), with rates of 73.0% at 5 years and 66.4% at 8 years (12). The reasons for these results are unknown but could be related to patient selection, focal treatment of only the peripheral zone, or the reliability of the technical process used.…”

Section: Resultsmentioning

confidence: 99%

Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow

2017

View full text Add to dashboard Cite

Magnetic resonance imaging (MRI) produces better soft tissue contrast than does ultrasonography (US) or computed tomography (CT) for visualizing male pelvic anatomy and prostate cancer. Better visualization of the tumor and organs at risk could allow better conformation of the dose to the target volumes while at the same time minimizing the dose to critical structures and the associated toxicity. Although the use of MRI for prostate brachytherapy would theoretically result in an improved therapeutic ratio, its implementation been slow, mostly because of technical challenges. In this review we describe the potential role of MRI at different steps in the treatment workflow for prostate brachytherapy: for patient selection, treatment planning, in the operating room, or for post-implant assessment. We further present the current clinical experience with MRI-guided prostate brachytherapy, both for permanent seed implantation and high-dose-rate brachytherapy.

show abstract

“…This approach represents a simplified alternative to existing local treatments relaying on the use of sophisticated medical devices (i.e. radioactive seeds) [25]. The local treatment of tumor lesions is becoming increasingly popular as part of multimodal approaches aiming at limiting systemic toxicity while promoting anti-tumor immune responses also able to act distally against untreated tumor lesions (abscopal effect) [26–31].…”

Section: Discussionmentioning

confidence: 99%

AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies

et al. 2017

View full text Add to dashboard Cite

The oxidized version of Avidin, known as AvidinOX, was previously shown to link to tissue proteins upon injection or nebulization, thus becoming a stable receptor for biotinylated therapeutics. AvidinOX is currently under clinical investigation to target radioactive biotin to inoperable tumor lesions (ClinicalTrials.gov NCT02053324). Presently, we show that the anti-ErbB2 monoclonal antibodies Trastuzumab and Pertuzumab can be chemically biotinylated while maintaining their biochemical and biological properties. By using several and diverse experimental conditions, we show that when AvidinOX is conjugated to tumor cells, low antibody concentrations of biotinylated Trastuzumab (bTrast) or Pertuzumab (bPert) prevent internalization of ErbB2, induce endoplasmic reticulum stress, cell cycle arrest and apoptosis leading to inhibition of proliferation and ErbB2 signaling. Moreover, we found that the treatment is able to induce down-modulation of ErbB2 thus bypassing the known resistance of this receptor to degradation. Interestingly, we show that AvidinOX anchorage is a way to counteract agonistic activities of Trastuzumab and Pertuzumab. Present data are in agreement with previous observations from our group indicating that the engagement of the Epidermal Growth Factor Receptor (EGFR) by AvidinOX-bound biotinylated Cetuximab or Panitumumab, leads to potent tumor inhibition both in vitro and in animal models. All results taken together encourage further investigation of AvidinOX-based treatments with biotinylated antibodies directed to the members of the EGFR family.

show abstract

Long-term results of permanent implant prostate cancer brachytherapy: A single-institution study of 675 patients treated between 1999 and 2003

Cited by 28 publications

References 40 publications

Low‐dose‐rate brachytherapy for prostate cancer: outcomes at >10 years of follow‐up

Low‐dose‐rate brachytherapy for prostate cancer: outcomes at >10 years of follow‐up

Clinical use of magnetic resonance imaging across the prostate brachytherapy workflow

AvidinOX-anchored biotinylated trastuzumab and pertuzumab induce down-modulation of ErbB2 and tumor cell death at concentrations order of magnitude lower than not-anchored antibodies

Contact Info

Product

Resources

About